Olmesartan Tecnigen (Olmesartan Medoxomil)

Olmesartan works primarily on the renin‑angiotensin‑aldosterone system to lower blood pressure.

• Hypertension: helps achieve target blood pressure and reduces cardiovascular risk.
• Diabetic nephropathy: slows progression of kidney damage associated with diabetes.
• Heart failure: used as part of combination therapy to improve outcomes in patients with reduced ejection fraction.

• Olmesartan medoxil is a selective antagonist of the angiotensin II type 1 (AT1) receptor. By blocking AT1, it prevents angiotensin II‑mediated vasoconstriction, aldosterone secretion, and sympathetic activation, leading to vasodilation, reduced sodium and water retention, and ultimately lower systemic blood pressure.

Adverse reactions reported with olmesartan are generally mild to moderate.

Common Side Effects

• Dizziness
• Headache
• Fatigue
• Nasal congestion
• Diarrhea
• Upper respiratory tract infection

Serious or Rare Side Effects

• Angio‑edema
• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Liver enzyme elevations
• Bullous pemphigoid (rare skin reaction)

Olmesartan should be used with caution in several clinical situations.

• Pregnancy: contraindicated in the second and third trimesters due to risk of fetal toxicity.
• Renal impairment: dose adjustment may be required; monitor kidney function.
• Hyperkalemia risk: avoid concomitant potassium‑saving diuretics unless indicated.
• Drug‑induced liver injury: monitor liver enzymes if patient has pre‑existing liver disease.
• Elderly patients: start at lower dose and titrate slowly.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan may interact with several other medicines, requiring monitoring or avoidance.

Major Interactions (Avoid)

• Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): increased risk of renal dysfunction and hyperkalaemia.
• Potassium‑supplementing agents or potassium‑sparing diuretics: may cause dangerous hyperkalaemia.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Diuretics: may enhance hypotensive effect, especially at therapy initiation.
• Lithium: may increase serum lithium levels, requiring dose adjustment.
• Rifampin: may reduce olmesartan plasma concentrations.
• CYP450 inhibitors/inducers: may modestly affect olmesartan metabolism.